References
- Abrams DI, Guzman M. 2015. Cannabis in cancer care. Clin Pharmacol Ther. 97(6):575–586.
- Badowski ME, Yanful PK. 2018. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag. 14:643–651.
- Cressey D. 2015. The cannabis experiment. Nature. 524(7565):280–283.
- Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. 2016. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal. 128:201–209.
- Giacoppo S, Bramanti P, Mazzon E. 2017. Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation. Mult Scler Relat Disord. 17:22–31.
- Fellermeier M, Eisenreich W, Bacher A, Zenk MH. 2001. Biosynthesis of cannabinoids: incorporation experiments with 13C-labeled glucoses. Eur J Biochem. 268(6):1596–1604.
- Meng Q, Buchanan B, Zuccolo J, Poulin MM, Gabriele J, Baranowski DC. 2018. A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products. PLoS One. 13(5):e0196396.
- Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M. 2018. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep. 18(2):8.
- Romano LL, Hazekamp A. 2013. Cannabis oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids. 1(1):1–11.
- Russo EB. 2011. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 163(7):1344–1364.
- Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, et al. 2015. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 313(24):2456–2473.